FDA Approves KALYDECO — Vertex Pharmaceuticals Incorporated

# FDA Approves Vertex Pharmaceuticals' KALYDECO for Cystic Fibrosis Vertex Pharmaceuticals Incorporated received FDA approval for KALYDECO (ivacaftor), an oral medication representing a significant advancement in cystic fibrosis treatment and establishing the company as a leader in precision medicine therapeutics. The approval marks a major market opportunity for Vertex in the orphan drug space, as KALYDECO targets a specific genetic mutation affecting a relatively small patient population, positioning the company for substantial revenue growth with limited competitive pressure.